Business UpdateJul 31, 2026, 07:07 AM
Ocugen to Present Gene Therapy Platform at Investor Conferences
AI Summary
Ocugen, Inc. announced it will present its innovative modifier gene therapy platform at two upcoming investor conferences in August 2026. The company will participate in a panel discussion at the Oppenheimer 4th Annual Biotech in the Berkshires Summit on August 4, 2026. Additionally, Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, will deliver a fireside chat at the Canaccord 46th Annual Growth Conference on August 11, 2026, with a webcast available for the latter event.
Key Highlights
- Ocugen will present its modifier gene therapy platform at two investor conferences in August 2026.
- The first presentation is at the Oppenheimer 4th Annual Biotech in the Berkshires Summit on August 4, 2026.
- The Oppenheimer event will be a panel discussion titled "Beyond the Readout: Building Durable Value in Rare Diseases & Gen Meds."
- The second presentation is at the Canaccord 46th Annual Growth Conference on August 11, 2026.
- Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, will present at the Canaccord event.
- A webcast of the Canaccord presentation will be available on the Company's investor relations website.
Price Impact
More from OCGN